BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 6383020)

  • 1. Clinical trial of a new trivalent measles-mumps-rubella vaccine in young children.
    Vesikari T; Ala-Laurila EL; Heikkinen A; Terho A; D'Hondt E; André FE
    Am J Dis Child; 1984 Sep; 138(9):843-7. PubMed ID: 6383020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined trivalent and bivalent measles, mumps and rubella virus vaccination. A controlled trial.
    Swartz TA; Klingberg W; Klingberg MA
    Infection; 1974; 2(3):115-7. PubMed ID: 4606362
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical evaluation of a new measles-mumps-rubella trivalent vaccine.
    Schwarz AJ; Jackson JE; Ehrenkranz NJ; Ventura A; Schiff GM; Walters VW
    Am J Dis Child; 1975 Dec; 129(12):1408-12. PubMed ID: 128287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical evaluation of a new measles-mumps-rubella combined live virus vaccine in the Dominican Republic.
    Ehrenkranz NJ; Ventura AK; Medler EM; Jackson JE; Kenny MT
    Bull World Health Organ; 1975; 52(1):81-5. PubMed ID: 764997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the Urabe Am 9-Schwarz and Jeryl Lynn-Moraten combinations of mumps-measles vaccines in young children.
    Vesikari T; André FE; Simoen E; Florent G; Ala-Laurila EL; Heikkinen A; Kuusinen H; Terho A
    Acta Paediatr Scand; 1983 Jan; 72(1):41-6. PubMed ID: 6344551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A field with a liver measles-mumps-rubella vaccine.
    Walters VW; Miller SA; Jackson JE; Kenny MT
    Clin Pediatr (Phila); 1975 Oct; 14(10):928-33. PubMed ID: 1100294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of live attenuated varicella vaccine (Oka-RIT strain) and combined varicella and MMR vaccination in 13-17-month-old children.
    Vesikari T; Ohrling A; Baer M; Delem A; Bogaerts H; André FE
    Acta Paediatr Scand; 1991 Nov; 80(11):1051-7. PubMed ID: 1661057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A controlled trial for evaluating two live attenuated mumps-measles vaccines (Urabe Am 9-Schwarz and Jeryl Lynn-Moraten) in young children.
    Popow-Kraupp T; Kundi M; Ambrosch F; Vanura H; Kunz C
    J Med Virol; 1986 Jan; 18(1):69-79. PubMed ID: 3511182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous administration of a diphtheria and tetanus toxoids and acellular pertussis vaccine with measles-mumps-rubella and oral poliovirus vaccines.
    Rothstein EP; Bernstein HH; Glode MP; Laussucq S; Nonenmacher J; Long SS; Hackell JG
    Am J Dis Child; 1993 Aug; 147(8):854-7. PubMed ID: 8394646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of live trivalent vaccine of measles AIK-C strain, mumps Hoshino strain and rubella Takahashi strain, by virus-specific interferon-gamma production and antibody response.
    Nakayama T; Urano T; Osano M; Nakagawa M; Maehara N; Sasaki K; Yamamura AM; Makino S
    Microbiol Immunol; 1990; 34(6):497-508. PubMed ID: 2120551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of a combined live attenuated measles, mumps, rubella, and varicella vaccine (MMR(II)V) in healthy children.
    Watson BM; Laufer DS; Kuter BJ; Staehle B; White CJ; Starr SE
    J Infect Dis; 1996 Mar; 173(3):731-4. PubMed ID: 8627041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Certain problems with limits of immunity against measles, mumps and rubella].
    Magdzik W
    Przegl Epidemiol; 1993; 47(1-2):47-53. PubMed ID: 8351387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years.
    Johnson CE; Kumar ML; Whitwell JK; Staehle BO; Rome LP; Dinakar C; Hurni W; Nalin DR
    Pediatr Infect Dis J; 1996 Aug; 15(8):687-92. PubMed ID: 8858673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunization of healthy children with measles-mumps-rubella trivalent vaccine simultaneously given with varicella vaccine].
    Takayama N; Kidokoro M; Suzuki K; Morita M
    Kansenshogaku Zasshi; 1992 Jun; 66(6):776-80. PubMed ID: 1331262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
    Zäch K; Nicoara C; Germann D; Matter L
    Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a combined vaccine against measles-mumps-rubella produced on human diploid cells.
    Just M; Berger R; Glück R; Wegmann A
    Dev Biol Stand; 1986; 65():25-7. PubMed ID: 3549399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Morbidity, vaccine coverage and immunity against measles, mumps and rubella in a Gallician population from 2 to 5 years old].
    Vázquez Fernández E; López Rois F; Vázquez Carrete JA; Gómez Tato B; Alvarez Ares M
    An Esp Pediatr; 1987 Jul; 27(1):27-31. PubMed ID: 3662251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibodies to measles, mumps and rubella in UK children 4 years after vaccination with different MMR vaccines.
    Miller E; Hill A; Morgan-Capner P; Forsey T; Rush M
    Vaccine; 1995 Jun; 13(9):799-802. PubMed ID: 7483800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes of the immunological patterns against measles, mumps and rubella. A vaccination programme studied 3 to 7 years after the introduction of a two-dose schedule.
    Christenson B; Böttiger M
    Vaccine; 1991 May; 9(5):326-9. PubMed ID: 1872016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased measles antibody response after measles-mumps-rubella vaccine in infants with colds.
    Krober MS; Stracener CE; Bass JW
    JAMA; 1991 Apr; 265(16):2095-6. PubMed ID: 2013930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.